HomeAI · summaries
Storia in 3 fonti
Petrelintide, a novel amylin analog, induces 10% weight loss, very well tolerated
NEW ORLEANS — Weekly petrelintide demonstrated clinically meaningful weight loss through 42 weeks and was well tolerated among adults with obesity or overweight without diabetes, according to results from the phase 2 ZUPREME-1 trial.Petrelintide (Roche/Zealand Pharma) is a long-acting human amylin analog that is being investigated as a once-weekly injectable medication for obesity.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options,…
- ·
statnews.com
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
